Steve Arshinoff, MD MD
Steve A. Arshinoff MD FRCSC was born in Montreal, Quebec, Canada, graduated in Medicine from Baylor College of Medicine, in Houston, Texas, and completed his ophthalmic training at The University of Toronto, Canada, where he is Professor, Department of Ophthalmology and Vision Sciences. His areas of research interest include ophthalmic viscosurgical devices and related surgical techniques, phacoemulsification machine design, immediately sequential bilateral cataract surgery, post-operative endophthalmitis prophylaxis, and medical outreach programs. He is on the Editorial Board of the Journal of Cataract and Refractive Surgery and has authored more than 300 peer-reviewed publications, 38 medical textbook chapters and 1 book (Immediately Sequential Bilateral Cataract Surgery). He has presented >1,100 academic lectures worldwide. Dr. Arshinoff is the designer of the OMA-CNIB (Ontario Medical Association - Canadian National Institute for the Blind) Mobile Medical Eye Care Unit (MMECU) and is the medical director of this program to the North of Ontario, Canada (an area = 1.25 x Texas). He is the Founding President of the Toronto Ophthalmological Society, the Eye Foundation of Canada, and the International Society of Bilateral Cataract Surgeons (iSBCS) and is a Past President of the International Intra-ocular Implant Club, the parent society of the American, European and all other Societies of Cataract and Refractive Surgery globally.
Financial disclosure: Dr. Arshinoff has/had an affiliation (financial or otherwise) with a commercial organization:
1. Alcon
2. Entod Pharmaceuticals
3. I-Med Pharmaceuticals
4. Zeiss
5. Rayner
6. ArcticDx
Sessions auxquelles Steve Arshinoff, MD MD participe
Dimanche 16 Juin, 2019
Samedi 11 Juin, 2022
Jeudi 8 Septembre, 2022
Vendredi 20 Juin, 2025
Author’s Name(s): Steve Arshinoff, Runjie Bill Shi, Brenda TaoAuthor’s Disclosure Block: Steve Arshinoff: Alcon, Employment/honoraria/consulting fees, BVI, Employment/honoraria/consulting fees, Bohus Biotech, Employment/honoraria/consulting fees, Rayner, Employment/honoraria/consulting fees, carl Zeiss Meditech, Employment/honoraria/consulting fees; Runjie Bill Shi: none; Brenda Tao: noneAbstract BodyPurpose:To determine the...
Sessions auxquelles Steve Arshinoff, MD MD assiste
Jeudi 15 Juin, 2023
Please join us for a glass of cheer and help us celebrate the 2023 COS Annual Meeting and Exhibition. This event is a great opportunity to network with our international speakers, special guests, sponsors, and exhibitors. Renew old acquaintances and make new friends with colleagues from across Canada.
Vendredi 16 Juin, 2023
*Le petit déjeuner sera servi à compter de 06h00*
Learning Objectives:At the end of this session, participants will be able to:Review how to apply Quality Improvement strategies to improve patient safetyBe familiar with the presentation and histology of hereditary benign intraepithelial dyskeratosis, and be able to distinguish it from other conjunctival lesions including conjunctival intraepithelial neoplasia.Des...
Objectifs d’apprentissageÀ la fin de la séance, les participants pourront :Explorer la nouvelle technologie en matière de LIO et la biométrie.Discuter de l’utilisation de LIO toriques.Examiner des perles en matière de chirurgie de la cataracte après l’utilisation de LIO phaques.Rôles CanMEDS : Expert médical, Érudit
Objectifs d’apprentissageÀ la fin de la séance, les participants pourront :Examiner les états comorbides courants présents chez les patients atteints de cataracte.Discuter de la communication du risque pour une chirurgie de la cataracte.Explorer le rôle de l’ergonomie en milieu de travail.Rôles CanMEDS : Expert médical, Érudit
Author Block: Steve A. Arshinoff . University of Toronto. Author Disclosure Block: Steve Arshinoff: S.A. Arshinoff: Any direct financial payments including receipt of honoraria; Name of for-profit or not-for-profit organization(s); Alcon, Zeiss, Rayner, Cima, Arctic Dx. Any direct financial payments including receipt of honoraria; Description of relationship(s); consultant. Abstract Body:
Objectifs d’apprentissageÀ la fin de la séance, les participants pourront :Examiner les antécédents et les perceptions du patient par rapport à la CCBIS.Explorer les tendances dans les stratégies relatives aux LIO.Discuter d’une chirurgie réfractive de la cataracte de qualité supérieure.Rôles CanMEDS : Expert médical, Érudit
Samedi 17 Juin, 2023
Learning Objectives:At the end of this session, participants will be able to:Elucidate the cause and mechanism of DVD.Identity indications of Light adjustable lensXX
Objectifs d’apprentissageÀ la fin de la séance, les participants pourront :Décrire la façon dont les cultures de cellules endothéliales cornéennes peuvent servir dans le traitement d’une insuffisance cellulaire endothéliale cornéenne.Décrire la façon dont la neurotisation cornéenne est réalisée et la comparer à d’autres modalités de traitement pour le traitement d’ulcères cornéens neurotrophiques.Décrire la façon dont une g...
Objectifs d’apprentissageÀ la fin de la séance, les participants pourront :Améliorer les stratégies chirurgicales dans le cas d’une chirurgie de la cataracte de routine.Élaborer une approche en matière de chirurgie de la cataracte complexe : techniques, stratégies et instrumentation.Rôles CanMEDS : Expert médical, Érudit
Authors (233 & 238): Miguel Angel Hernandez-Delgado1, Yuridia Garcia-Espindola2, Mélanie Hébert3. 1Instituto Tecnologico y de Estudios Superiores de Monterrey, 2 Universidad Michoacana de San Nicolas de Hidalgo, 3Department of Ophthalmology, Hôpital Saint-Sacrement, CHU de Québec - Université Laval.Author Disclosures (233 & 238): M.A. Hernand...
Dimanche 18 Juin, 2023
Author Block: Mélanie Hébert 1, Ryan Hendrick2, Keith Perry2, Mohammed Al-Kaabi3, Anna Polosa3, Marie-Josée Aubin3. 1Hôpital Saint-Sacrement, CHU de Québec - Université Laval, 2Université de Montréal, 3Centre universitaire d'ophtalmologie, Hôpital Maisonneuve-Rosemont.Author Disclosure Block: M. Hébert: Funded grants or clinical trials; Name of for-profit or not-for-profit organization(s); Bayer, Fighting Blindness Canada, Vision Health Research...